(Reuters) - Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback